Diagnostics HeadwindsSofter-than-expected COVID sales, ongoing disruption from VBP in China, and recent changes in HIV funding were largely responsible for lower-than-expected Diagnostics sales.
Guidance RevisionABT has lowered its 2025 organic sales growth guidance due to transitory challenges in Diagnostics, such as reduced COVID testing and slower recovery in China.
Non-MedTech SegmentsABT's non-MedTech segments, which account for about 55% of revenue, remain a source of disruption.